FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications By Ogkologos - August 19, 2026 24 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies Source RELATED ARTICLESMORE FROM AUTHOR Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe New Translations of the ESMO Patient Guides Available in Estonian Trend in Survival Benefit with a Combination of Spartalizumab Plus Dabrafenib and Trametinib Over Targeted Therapy Alone for BRAF V600-mutated Metastatic Melanoma MOST POPULAR FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with... November 6, 2024 Targeting Inflammation Emerges as a Strategy for Treating Cancer August 19, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib March 27, 2026 Drug Combination May Have Potential for Cancers with TP53 Mutations April 4, 2024 Load more HOT NEWS Addressing the Challenges of Cancer Misinformation on Social Media A Large Case-Control Study of Hodgkin Lymphoma Survivors Suggests a Dose-Response... ASCO 2021 news: follow-up treatments pave the way EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab
